Navigation Links
ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease
Date:8/7/2008

KIRKLAND, Wash., Aug. 7 /PRNewswire/ -- ProteoTech Inc. (ProteoTech) today announced that it has completed regulatory Investigational New Drug (IND) requirements and has been cleared by the FDA to initiate its Phase 1 human clinical trial on Exebryl-1(R), a novel small molecule drug targeting toxic beta-amyloid protein accumulation for the treatment of Alzheimer's disease. ProteoTech initiated its Phase 1 human trial on July 29, 2008.

At the 2008 International Conference on Alzheimer's disease in Chicago last week, ProteoTech presented remarkable efficacy data in Alzheimer's transgenic mice, whereby Exebryl-1(R) lowered brain beta-amyloid protein load by greater than 30-50%, correlating with marked improvements in memory in these animals. Toxic and insoluble beta-amyloid protein accumulation is believed to be an important part of the disease progression and memory impairment observed in all patients with Alzheimer's disease. Data was also presented demonstrating oral bioavailability and blood-brain-barrier penetration of Exebryl-1(R).

Exebryl-1(R) is a novel small molecule drug developed at ProteoTech from its unique library of small molecule compounds designed to target specific amyloid diseases. Over six years of pre-clinical in vitro and in vivo testing led to the development of Exebryl-1(R) that is believed to prevent beta-amyloid protein formation, deposition, and accumulation at all stages of the disease progression. In addition, Exebryl-1(R) also contributes to a reduction and clearance of beta-amyloid protein deposits already existing in the brain as shown by a significant and marked reduction in brain amyloid plaques in older Alzheimer's transgenic animals.

Initial studies suggest that Exebryl-1(R) may also have an important dual capacity by inhibiting and reducing tau protein from forming paired helical filaments, important in neurofibrillary tangle formation. The presence of neurofibrillary tangles in brain containing tau prote
'/>"/>

SOURCE ProteoTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. AcroMetrix Renews Contract With Group Services for Americas Blood Centers
11. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2008)...development and validation of non-animal alternati... MatTek Corporation today announce...AC) endorsed the scientific validity of the Modifi...ber meeting. ESAC concluded that the Modified Epi...or the prediction of skin irritating and non-irrit...
(Date:12/17/2008)... of Its Kind; 80 Percent of Trauma Patient,s Face ...wire/ -- A multi-disciplinary team of doctors and ...e first near-total face transplant in the United...ed within the past two weeks, surgeons transplante... facial trauma -- essentially replacing her entire...
(Date:12/17/2008)...swire-FirstCall/ -- Medivation, Inc.,(Nasdaq: M...t enrollment in a,Phase 1-2 dose-escalation clini... antagonist, in castration-resistant prostate canc...the U.S. Food and Drug Administration (FDA) to,ad... The open-label, U.S. Phase 1-2 study evaluated ...
(Date:12/17/2008)... December 17 NicOx,S.A....ve results of a,pre-specified pooled analysis of ...301, 302 and 303 pivotal phase 3 studies for napro...icant reduction in systolic and diastolic blood,p...bid over the whole 13 week,period (p<0.001 for...
Breaking Medicine Technology:EpiDerm's Skin Irritation Test Fully Validated in European Union 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 3Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 2NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 3NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 5Lead Exposure in Childhood Linked to Criminal Behavior Later 20416 1Lead Exposure in Childhood Linked to Criminal Behavior Later 20416 2Lead Exposure in Childhood Linked to Criminal Behavior Later 20416 3Study shows pine bark naturally reduces cardiovascular risk factors in diabetics 20414 1Study shows pine bark naturally reduces cardiovascular risk factors in diabetics 20414 2Study shows pine bark naturally reduces cardiovascular risk factors in diabetics 20414 3Atherotech to Exhibit The VAP Test at ADA 2008 Meeting in San Francisco 20409 1Atherotech to Exhibit The VAP Test at ADA 2008 Meeting in San Francisco 20409 2Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 1Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 2Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 3Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 4Streamline Healths Document Management Solution Integrated into Oacis Allowing Clinicians to Access Patients Information Either Scanned or Electron 20403 5
... 19, 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AO...ers at Loma Linda University Medical Center,Natio...iversity,showing that one of the Company,s metallo...rotection of healthy normal cells in mice,with pro...The study,also showed that the compound did not in...
...rgeting Pro-Inflammatory,Protein -, GAITHERSBURG, ...mmune, Inc. today announced the publication of pre...mobility group box,protein-1 (HMGB1), a nuclear DN...toimmune diseases such as systemic lupus,erythemat... to be,published in the May 2007 issue of Nature I...
Other Medicine Technology:Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a,Protector of Healthy Normal Cells from Cancer Radiation Therapy 2Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a,Protector of Healthy Normal Cells from Cancer Radiation Therapy 3MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3
(Date:1/8/2009)...nues to drive overall performance , , DALLAS, J...ixCorp(R)), (Nasdaq: ZIXI ), the leader in hoste... today offered a corporate update by its chief exe...ear on a high note in our Email Encryption busines... the fourth quarter," said Spurr. "Our new first-...
(Date:1/8/2009)...ides minimally-invasive treatment for Peripheral A...wire/ -- The Heart Hospital of Austin is the fir...s RF PowerAssert(TM) Magnetic Guidewire to success...mplete blockages in patients with peripheral arter...iologist, Frank Zidar, M.D. used the new device on...
(Date:1/8/2009)...- St. Jude Children,s Research,Hospital(R) and St...ner-Up,Camilo Villegas has increased his commitme...Singh,s donation of $5,000 to St. Jude for every e...t. Jude is a powerful program that,has united Vil...GA star Morgan,Pressel, along with the Golf Chann...
(Date:1/8/2009)... , NEW YORK, Jan. 8 U...rations of North America today committed to raise ...ds in southern Israel, part of a major initiative ...uring the current conflict with Hamas, the terrori... , The funds will enhance programs supported by t...
Breaking Medicine News(10 mins):Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 2Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 4Health News:Heart Hospital of Austin First in World to Use New Device for Blocked Arteries 2Health News:Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude 2Health News:Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude 3Health News:Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude 4Health News:UJC and Jewish Federations of North America Commit $10 Million for Needs in Southern Israel 2
...ng 20 paintings by renowned masters like M.F. Husa...ment a similar theme to be etched out at Sunday's ...Week. "There are different kinds of desire in a h... fulfilled, some only dream about it. But it's som...
...n people as young as 16 whereas the phenomenon onc... says. "Nobody can escape stress in modern day li...cts like a male hormone and causes the thinning of... Shah said. "Initially, we used to see this begin...
...Saturday in Burhanpur district of Madhya Pradesh i...Maharashtra testing positive for the deadly bird f...ation will also be paid to 323 affected poultry ow...cted," said Rajesh Rajora, commissioner of the sta...
...University are pumping for a controversial theory,...e forced// into "dark states" where they can be ea... idea appears to contravene some of the most accep...y, not long ago dismissed as impossible by much of...
Other Medicine News:Health News:India Fashion Week Reveals - 'The Story Of Desire' 2Health News:Stress Can Cause Hair loss at 16 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 3
CenterPointLock Large Drainable Pouch
CenterPointLock Cut-to-Fit SoftFlex Skin Barrier, Flat, without tape
CenterPointLock Cut-to-Fit Flextend Skin Barrier, Flat
Inquire
Medicine Products: